eHIV Review

Understanding AE in the New ART Regimens

In this issue:

Antiretroviral therapy is continually improving, as new agents and combinations of agents become available that decrease the severe morbidity and mortality associated with HIV infection. As patients’ lifespans increase, it becomes more and more important for clinicians to consider the potential short-term and especially the potential long-term adverse effects of the medications they prescribe.

In this issue, Dr. Cody Chastain from the Division of Infectious Diseases at Vanderbilt University Medical Center reviews the recent postmarketing surveillance that goes beyond the clinical trials to identify previously unrecognized adverse events associated with some of the newer HIV medications.

Learning objectives:

• Discuss the current evidence associating an increased rate of neural tube defects with using dolutegravir in pregnancy.
• Compare the association of darunavir’s cardiovascular events profile with the emerging benefits/possible risks of dolutegravir’s lipid-lowering and weight-gain effects.
• Describe the frequency and severity of neuropsychiatric adverse effects related to integrase strand transfer inhibitors (INSTI), including dolutegravir.